Accord BioPharma Launches Two Denosumab Biosimilars
RALEIGH, N.C., July 23, 2026 Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, has announced the commercial...
Multiple Myeloma
Advertisement
Johnson & Johnson Advances Myeloma Care with TECVAYLI and TALVEY
RARITAN, N.J., July 23, 2026 Johnson & Johnson has announced positive topline results from the Phase 3 MonumenTAL-6 clinical...
Organon, Samsung Bioepis Strengthen Australia Biosimilar Portfolio
SYDNEY, Australia & INCHEON, South Korea, July 16, 2026 Organon and Samsung Bioepis have expanded their longstanding partnership through...
ARUP Launches First Clinical Spectral Flow MRD Assay
SALT LAKE CITY, July 20, 2026 ARUP Laboratories has introduced ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry,...
Cellectar Publishes Phase 1 Iopofosine Data
FLORHAM PARK, N.J., July 15, 2026 Cellectar Biosciences announced the publication of results from its Phase 1 dose-escalation study...
Advertisements
Universal Brain Earns FDA 510(k) for Brain Function Technology
SAN FRANCISCO, Calif., July 13, 2026 Universal Brain has achieved a significant regulatory milestone after receiving U.S. Food and...
Leads Biolabs Secures Six ESMO 2026 Research Presentations
NANJING, China, July 13, 2026 Leads Biolabs has strengthened its position in global cancer immunotherapy after announcing that six...
Sanofi Secures FDA Nod for Sarclisa Escena
PARIS, July 10, 2026 Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Sarclisa Escena® (isatuximab-irfc)...
Sanofi Wins Japan Approval for Sarclisa SC in Myeloma
PARIS | June 19, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the...
Sanofi Wins EU Approval for Sarclisa SC in Multiple Myeloma
PARIS, France, June 8, 2026 Sanofi announced that the European Commission has approved Sarclisa® (isatuximab) subcutaneous (SC) for the...
Advertisement
